Thus, the STING pathway and alternative-STING pathway mediate immunomodulation in HRD tumors and depending on the molecular profile of the tumor can either activate or inhibit the immune response. The gene discussed is STING1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.